The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2008, 180, 3627 -3635
Copyright © 2008 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berzofsky, J. A.
Right arrow Articles by Terabe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berzofsky, J. A.
Right arrow Articles by Terabe, M.

NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis1

Jay A. Berzofsky2 and Masaki Terabe2

Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

NKT cells are true Ag-specific T cells that also have innate properties and form a bridge between the innate and adaptive immune systems. Distinct NKT cell subsets play positive and negative regulatory roles and define a new immunoregulatory axis with broad implications for tumor immunity and other immunological and disease settings.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. We apologize for not citing all works on the topic because of space limitations.

2 Address correspondence and reprint requests to Dr. Masaki Terabe or Dr. Jay A. Berzofsky, Vaccine Branch, National Cancer Institute, Building 10, Room 6B-12, Bethesda, MD 20892-1578. E-mail address: terabe{at}mail.nih.gov or berzofsk{at}helix.nih.gov

3 Abbreviations used in this paper: DC, dendritic cell; {alpha}GalCer, {alpha}-galactosylceramide; EAE, experimental autoimmune encephalitis; KO, knockout; Treg, T regulatory (cell).




This article has been cited by other articles:


Home page
Cancer Res.Home page
H. Yuling, X. Ruijing, L. Li, J. Xiang, Z. Rui, W. Yujuan, Z. Lijun, D. Chunxian, T. Xinti, X. Wei, et al.
EBV-Induced Human CD8+ NKT Cells Suppress Tumorigenesis by EBV-Associated Malignancies
Cancer Res., October 15, 2009; 69(20): 7935 - 7944.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. J. Subleski and J. R. Ortaldo
Editorial: NKT cells: to suppress or not to suppress, that is the question
J. Leukoc. Biol., October 1, 2009; 86(4): 751 - 752.
[Full Text] [PDF]


Home page
J. Immunol.Home page
A. Astrakhan, H. D. Ochs, and D. J. Rawlings
Wiskott-Aldrich Syndrome Protein Is Required for Homeostasis and Function of Invariant NKT Cells
J. Immunol., June 15, 2009; 182(12): 7370 - 7380.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
L. Mortara, V. Frangione, P. Castellani, A. De Lerma Barbaro, and R. S. Accolla
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions
Int. Immunol., June 1, 2009; 21(6): 655 - 665.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
M. Terabe and J. A. Berzofsky
NKT Cells and Cancer: Two Subsets Form a New Immunoregulatory Axis
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 203 - 208.
[Full Text] [PDF]


Home page
J. Immunol.Home page
M. Elkabets, Y. Krelin, S. Dotan, A. Cerwenka, A. Porgador, R. G. Lichtenstein, M. R. White, M. Zoller, Y. Iwakura, C. A. Dinarello, et al.
Host-Derived Interleukin-1{alpha} Is Important in Determining the Immunogenicity of 3-Methylcholantrene Tumor Cells
J. Immunol., April 15, 2009; 182(8): 4874 - 4881.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H.-J. Ko, J.-M. Lee, Y.-J. Kim, Y.-S. Kim, K.-A Lee, and C.-Y. Kang
Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine
J. Immunol., February 15, 2009; 182(4): 1818 - 1828.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.